Seaport Therapeutics, Inc.

SPTX Nasdaq SEC CIK 2042347
Follow Seaport Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$26.4M −17.1% vs same quarter last year
EPS, diluted −$0.49 +94.8% vs same quarter last year
Operating cash flow −$22.7M −43.9% vs same quarter last year
Operating income −$30.3M −19.3% vs same quarter last year
Net income by quarter
−$13.1M
−$15.1M
−$22.5M
−$25.4M
−$62.6M
−$26.4M
Q1 25 Q2 25 Q3 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing